Episode
ASCO 2026 Highlights – Part 2: Emerging Immunotherapy Strategies in Lung Cancer
- Podcast
- Lung Cancer Considered
- Published
- Jun 9, 2026
- Duration seconds
- 2418
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/lung-cancer-considered-246259/episodes/asco-2026-highlights-part-2-emerging-immunotherapy-strategies-in-lung-cancer/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/lung-cancer-considered-246259/asco-2026-highlights-part-2-emerging-immunotherapy-strategies-in-lung-cancer.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
In Part 2 of the ASCO 2026 Highlights series, hosts Dr. Narjust Florez and Dr. Stephen Liu are joined by Dr. Julie Brahmer and Dr. Solange Peters to discuss some of the most notable immunotherapy advances presented at the 2026 ASCO Annual Meeting. The conversation explores emerging data for PD-1/VEGF and PD-L1/VEGF bispecific antibodies, the growing role of antibody-drug conjugates in combination with immunotherapy, and promising new strategies targeting KRAS-mutant lung cancers, highlighting how these approaches may reshape the future treatment landscape. Guests: Julie R. Brahmer, MD, MSc, FASCO, FAIO The Marilyn Meyerhoff Professor of Thoracic Oncology Co-Leader, Cancer Immunology Research Program Co-Director, Upper Aerodigestive Cancers Program Director, Johns Hopkins Kimmel Cancer Center, Bayview Campus Professor Solange Peters, MD, PhD Chair of Medical Oncology Director of Oncology Department - CHUV Lausanne University Hospital